Announced Date: 2022-07-26 (July 26, 2022)
Asset Name: SKB-264 (MK-2870)
Licensor: Kelun-Biotech (subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd, China)
Licensee (Buyer): MSD (Merck & Co., Inc. USA)
.
Asset Modality: Antibody drug conjugate (ADC)
Asset Target: TROP2
Current Stage: Phase 3、Phase 2
Scope of Authority:
Kelun-Biotech has granted MSD global, exclusive rights to develop, manufacture and commercialize an investigational ADC.
Kelun-Biotech and MSD will also collaborate on the early clinical development of the investigational ADC.
.
Deal Detail:
Upfront payment of $35 million,
Milestone payments up to $901 million,
Total up to $935 million.
Plus tiered royalties on net sales.
.
Link:
Kelun-Biotech Announces Oncology Research Collaboration and License Agreement with MSD
Newsroom – Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
